The third quarter of 2025 closed amid growing macroeconomic strain, policy unpredictability and renewed investor focus on execution risk. While deal volume in life sciences and healthcare private capital has stabilized after...more
11/13/2025
/ Acquisitions ,
Artificial Intelligence ,
Biotechnology ,
California Privacy Protection Agency (CPPA) ,
Centers for Medicare & Medicaid Services (CMS) ,
CFIUS ,
Data Privacy ,
Department of Justice (DOJ) ,
Drug Pricing ,
Food and Drug Administration (FDA) ,
Government Shutdown ,
Healthcare ,
Life Sciences ,
Mergers ,
OIG ,
Pharmaceutical Industry ,
Popular ,
Private Equity ,
Private Funds ,
Regulatory Oversight ,
Reimbursements ,
Section 232 ,
Supply Chain ,
Tariffs ,
Transparency ,
Uyghur Forced Labor Prevention Act (UFLPA)
Dealmaking in Europe’s life sciences sector has been relatively muted in recent years, but the first half of 2025 has shown signs of strength as companies respond to the stark realities of an aging population -
Earlier this...more
7/23/2025
/ Acquisitions ,
Artificial Intelligence ,
EU ,
European Commission ,
Healthcare ,
Life Sciences ,
Mergers ,
Pharmaceutical Industry ,
Popular ,
Private Equity ,
Technology